JP Morgan Chase’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.28M Sell
60,000
-40,000
-40% -$3.55M ﹤0.01% 3437
2026
Q2
$9.12M Buy
100,000
+25,000
+33% +$2.09M ﹤0.01% 2883
2026
Q1
$5.96M Sell
75,000
-179,500
-71% -$14.8M ﹤0.01% 3152
2025
Q4
$21.7M Buy
254,500
+138,300
+119% +$11.3M ﹤0.01% 1999
2025
Q3
$9.04M Buy
116,200
+43,900
+61% +$3.43M ﹤0.01% 2809
2025
Q2
$5.65M Sell
72,300
-23,800
-25% -$1.77M ﹤0.01% 3032
2025
Q1
$6.97M Buy
96,100
+14,700
+18% +$1.05M ﹤0.01% 2874
2024
Q4
$6.03M Buy
81,400
+79,600
+4,422% +$5.57M ﹤0.01% 3190
2024
Q3
$119K Sell
1,800
-31,400
-95% -$2.28M ﹤0.01% 5627
2024
Q2
$3.07M Sell
33,200
-66,800
-67% -$5.92M ﹤0.01% 3422
2024
Q1
$9.6M Hold
100,000
– – ﹤0.01% 2533
2023
Q4
$7.62M Buy
+100,000
New +$6.96M ﹤0.01% 2724
2022
Q2
– Sell
-60,000
Closed -$7.06M – 6569
2022
Q1
$7.06M Buy
+60,000
New +$6.73M ﹤0.01% 2703
2020
Q4
– Sell
-35,000
Closed -$2.74M – 5708
2020
Q3
$2.74M Buy
+35,000
New +$2.73M ﹤0.01% 3016
2020
Q1
– Sell
-99,000
Closed -$7.7M – 5401
2019
Q4
$7.7M Hold
99,000
– – ﹤0.01% 2344
2019
Q3
$7.26M Hold
99,000
– – ﹤0.01% 2383
2019
Q2
$6.12M Sell
99,000
-343,200
-78% -$20.8M ﹤0.01% 2480
2019
Q1
$28.2M Buy
442,200
+380,400
+616% +$21.7M 0.01% 1303
2018
Q4
$3.16M Buy
+61,800
New +$3.13M ﹤0.01% 2931
2017
Q1
– Sell
-15,000
Closed -$469K – 5096
2016
Q4
$469K Sell
15,000
-135,000
-90% -$4.37M ﹤0.01% 3805
2016
Q3
$6.03M Sell
150,000
-67,500
-31% -$2.54M ﹤0.01% 2120
2016
Q2
$7.23M Buy
217,500
+7,500
+4% +$257K ﹤0.01% 2053
2016
Q1
$6.18M Buy
210,000
+188,949
+898% +$5.21M ﹤0.01% 2083
2015
Q4
$554K Buy
+21,051
New +$547K ﹤0.01% 3347
2015
Q1
– Sell
-159,600
Closed -$3.39M – 4112
2014
Q4
$3.39M Buy
+159,600
New +$3.21M ﹤0.01% 2653

Other funds holding EW

JP Morgan Chase's EW Position: Q3 2026 in Review

JP Morgan Chase increased its Edwards Lifesciences (EW) stake by 7.4% in Q3 2026, buying an estimated $149M and bringing the position to 24,464,600 shares worth $2.15B. The position accounts for 0.12% of the portfolio, ranked #173.

JP Morgan Chase first reported a position in EW in Q2 2013 and has held it in 54 quarters since. The position peaked at $2.22B in Q4 2025. 1,345 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • JP Morgan Chase held 24,464,600 shares of Edwards Lifesciences worth $2.15B as of Q3 2026.
  • JP Morgan Chase bought 1,681,425 Edwards Lifesciences shares in Q3 2026, an estimated $149M.
  • Edwards Lifesciences made up 0.12% of JP Morgan Chase's portfolio in Q3 2026, its #173 holding.
  • JP Morgan Chase first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 54 quarters since.
  • JP Morgan Chase's Edwards Lifesciences position peaked at $2.22B in Q4 2025.
  • 1,345 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.